Drug selection for simultaneous treatment of tuberculosis combined with hepatitis C virus infection.
10.3760/cma.j.cn501113-20201224-00675
- Author:
Shi Wu MA
1
;
Jia Rui WANG
1
;
Ya Mei ZHU
1
Author Information
1. Department of Infectious Diseases, 920th Hospital of Joint Logistics Support Force, Kunming 650032, China.
- Publication Type:Journal Article
- Keywords:
Antiviral treatment regimen;
Drug metabolism;
Drug-drug interactions;
Drug-induced liver injury;
Hepatitis C virus;
Liver cirrhosis;
Tuberculosis
- MeSH:
Chemical and Drug Induced Liver Injury;
Coinfection/drug therapy*;
Hepacivirus;
Hepatitis C/drug therapy*;
Humans;
Pharmaceutical Preparations;
Tuberculosis/drug therapy*
- From:
Chinese Journal of Hepatology
2022;30(1):113-116
- CountryChina
- Language:Chinese
-
Abstract:
Clinically, patients with tuberculosis (TB) combined with hepatitis C virus (HCV) infection often require simultaneous treatment. Consequently, when anti-HCV and TB drugs are used in combination drug-drug interactions (DDIs), anti-TB drug-induced hepatotoxicity, and liver disease states need to be considered. This paper focuses on discussing the metabolic mechanisms of commonly used anti-TB and HCV drugs and the selection options of combined drugs, so as to provide rational drug use for TB patients combined with HCV infection.
